A number of other analysts also recently commented on the company. HC Wainwright reduced their price objective on Aptose Biosciences from $8.50 to $6.00 and set a buy rating for the company in a research report on Wednesday, August 7th. Zacks Investment Research downgraded Aptose Biosciences from a buy rating to a hold rating in a research report on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the company’s stock. Aptose Biosciences has a consensus rating of Buy and a consensus target price of $5.25.
APTO traded down $0.01 during midday trading on Thursday, reaching $1.99. The company’s stock had a trading volume of 13,291 shares, compared to its average volume of 270,360. The stock has a market cap of $115.89 million, a P/E ratio of -2.35 and a beta of 1.70. The company has a fifty day simple moving average of $2.31 and a 200 day simple moving average of $2.27. The company has a current ratio of 11.27, a quick ratio of 11.27 and a debt-to-equity ratio of 0.04. Aptose Biosciences has a twelve month low of $1.57 and a twelve month high of $3.13.
Several hedge funds have recently made changes to their positions in the business. Gagnon Securities LLC bought a new position in shares of Aptose Biosciences during the 2nd quarter worth approximately $146,000. Patriot Financial Group Insurance Agency LLC lifted its position in shares of Aptose Biosciences by 7.9% during the 2nd quarter. Patriot Financial Group Insurance Agency LLC now owns 85,029 shares of the biotechnology company’s stock worth $221,000 after buying an additional 6,200 shares during the period. Rock Creek Group LP bought a new position in shares of Aptose Biosciences during the 2nd quarter worth approximately $255,000. Sanders Morris Harris LLC bought a new position in shares of Aptose Biosciences during the 2nd quarter worth approximately $572,000. Finally, Sigma Planning Corp bought a new position in shares of Aptose Biosciences during the 2nd quarter worth approximately $572,000. Institutional investors own 21.50% of the company’s stock.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Article: Trade Deficit
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.